Genmab A/S (GNMSF) Projected to Post Quarterly Earnings on Thursday

Genmab A/S (OTCMKTS:GNMSF) is anticipated to issue its results after the market closes on Thursday, August 6th. Analysts expect Genmab A/S to post earnings of $3.53 per share and revenue of $1.1110 billion for the quarter.

Genmab A/S Stock Performance

OTCMKTS:GNMSF opened at $289.16 on Thursday. The company has a debt-to-equity ratio of 0.87, a current ratio of 2.18 and a quick ratio of 2.17. The firm has a market cap of $17.80 billion, a PE ratio of 21.81 and a beta of 0.78. The firm has a 50 day simple moving average of $264.67 and a 200-day simple moving average of $281.35. Genmab A/S has a 1-year low of $216.31 and a 1-year high of $352.00.

Genmab A/S Company Profile

Genmab A/S is a biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer and other serious diseases. The company’s core expertise lies in its proprietary antibody platforms, including DuoBody®, HexaBody® and HexElect®, which enable the design and engineering of novel bispecific and enhanced-effector antibodies. Genmab’s science-driven approach integrates advanced protein engineering with insights into tumor biology to generate candidates that can engage the immune system, disrupt disease pathways and offer potential safety and efficacy advantages over conventional therapies.

Founded in 1999 and headquartered in Copenhagen, Denmark, Genmab has grown into a global organization with research and development facilities in Utrecht, the Netherlands, and commercial and clinical support offices in the United States.